Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancer
Details
Publication Year 2026-02-17,Volume 22,Issue #6,Page 699-707
Journal Title
Future Oncology
Publication Type
Research article
Abstract
INTRODUCTION: Objective response rate (ORR) is a common early endpoint in NSCLC trials, but its ability to predict overall survival (OS) is limited, especially for immunotherapy and targeted treatments. Alternative metrics like time to and depth of response are under evaluation as surrogate endpoints. METHODS: We analyzed pooled data from two randomized trials (OAK, POPLAR) comparing atezolizumab to docetaxel. Tumor response metrics, including RECIST response, time to response, response nadir, time to nadir, and duration of response (DOR), were correlated with OS using landmark survival analyses at 6, 12, and 18 weeks. RESULTS: Of 1137 patients, 31.2% achieved best RECIST response by week 6, with 17.5% and 12.7% by weeks 12 and 18. Patients with CR/PR had a 61% reduced risk of death versus those with PD. Longer DOR correlated with improved 12-month OS: 54.6% (6 weeks), 67.5% (12 weeks), and 82.1% (18 weeks). Mean target lesion reduction was -33.9%. Greater tumor reduction improved survival, but timing of nadir did not significantly affect OS or differ by treatment arm. CONCLUSION: Depth and duration of response are predictive of OS in NSCLC and may aid patient management, however are not adequate surrogate endpoints for OS in clinical trials.
Publisher
Taylor & Francis
Keywords
Tumor response; biomarker response; depth of response; duration of response; immunotherapy; non-small cell lung cancer; overall survival
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1080/14796694.2026.2630984
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2026-03-10 04:07:06
Last Modified: 2026-03-10 04:07:14
An error has occurred. This application may no longer respond until reloaded. Reload 🗙